We previously blogged about Dr. Reddy’s IPRs filed against MDS patents covering Celgene’s Revlimid®. Those IPRs attracted considerable attention because they were, for better or worse, one of the few data-points within the Revlimid® patent skirmishes we are guaranteed to see before the Bristol transaction closes. The Lotus IPR attacking one of Celgene’s multiple myeloma patent is another datapoint. The PTAB’s decision on whether to institute the IPR is due March 18. How much does Lotus IPR really matter?
Read MoreSince announcing the pending acquisition of Celgene ($CELG) by Bristol Myers ($BMY), investors have focused upon the patent-cases involving Revlimid®. There are multiple cases and petitions for inter partes review (IPRs) at various stages of resolution. The key question among investors is whether there will be any key milestones in those cases--especially during 2019 before the Bristol acquisition closes—that will clarify exactly when any of the pending generics will enter. In this post, we identify three potential milestones to watch for from the Revlimid® patent landscape in 2019.
Read MoreCelgene ($CELG) has announced plans to be acquired by Bristol Meyers Squibb ($BMY). A settlement conference is scheduled in the Hatch-Waxman patent case between Celgene and Dr. Reddy’s on January 10, 2019. Now that Bristol Meyers is at the table, will the parties be able to reach a settlement that couldn’t be reached before?
Read MoreOn August 3, Dr. Reddy’s filed three petitions for inter partes review (IPR) against three patents owned by Celgene and listed in the Orange Book for Revlimid®. Does this indicate that Celgene and Dr. Reddy’s are close to a settlement? If not, what are the take-aways?
Read MoreYesterday, we blogged about why the Markman hearing was cancelled in Celgene’s Revlimid® patent case against Dr. Reddy’s. Some analysts suggested that this is a positive indication of a settlement approaching with Dr. Reddy’s and possibly with all generics. We weigh in.
Read MoreA number of generics are moving in on Celgene's Revlimid. Leading the pack is Dr. Reddy’s, and although Celgene has asserted numerous patents against Dr. Reddy’s proposed generic, a single issue has crystallized in advance of an upcoming Markman hearing that could make or break the case.
Read More